Biogen, Inc. (BIIB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151226,
    "name": "Biogen, Inc.",
    "stock_name": "Biogen, Inc.",
    "full_name": "Biogen, Inc.",
    "name_url": "stocks-analysis/biogen-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "181.98",
    "chg": 1.8,
    "chgp": "1.0%",
    "dir": 1,
    "prev_price": "180.18",
    "mcapval": "24,088.10",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US09062X1037",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.05 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/biogen-inc-1151226-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Biogen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biogen-inc-technically-bullish-or-bearish-3673557",
        "imagepath": "",
        "date": "2025-11-05 11:19:31",
        "description": "As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and Bollinger Bands show a bearish signal on the monthly timeframe. The KST is bullish on the weekly and mildly bullish on the monthly, while Dow Theory indicates a mildly bullish trend on the weekly but no trend on the monthly.\n\nDespite the current bullish trend, Biogen's performance has been significantly underwhelming compared to the S&P 500, with a -14.07% return over the past year versus the S&P 500's 19.89%. Overall, the technical stance is bullish but with caution due to mixed signals in longer timeframes...."
      },
      {
        "title": "Is Biogen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biogen-inc-technically-bullish-or-bearish-3670750",
        "imagepath": "",
        "date": "2025-11-04 11:30:58",
        "description": "As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by a bullish daily moving average. However, the monthly MACD remains mildly bullish, and the Bollinger Bands indicate a mildly bearish stance for the monthly period. The KST shows a bullish signal weekly but bearish monthly, while the Dow Theory reflects a mildly bullish trend on a monthly basis. The OBV is mildly bullish for both weekly and monthly periods. \n\nDespite the bullish indicators, Biogen's performance has lagged significantly behind the S&P 500, with a year-to-date return of -0.97% compared to the S&P 500's 16.30%, and a one-year return of -12.86% versus 19.89% for the index. Overall, the current technical stance is bullish, but the strength is tempered by underperformance relative to the benchmark...."
      },
      {
        "title": "Is Biogen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biogen-inc-technically-bullish-or-bearish-3666339",
        "imagepath": "",
        "date": "2025-11-03 11:30:07",
        "description": "As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the monthly KST is bearish, suggesting some mixed signals. The Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, adding to the complexity of the trend. \n\nIn terms of performance, Biogen has underperformed against the S&P 500 across multiple periods, with a year-to-date return of 0.88% compared to the S&P 500's 16.30%, and a one-year return of -11.34% versus 19.89% for the index. Overall, the current technical stance is bullish, but the strength is tempered by some bearish indicators in the monthly timeframe...."
      },
      {
        "title": "Is Biogen, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biogen-inc-technically-bullish-or-bearish-3664454",
        "imagepath": "",
        "date": "2025-11-02 11:16:07",
        "description": "As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by a bullish daily moving average, while the monthly MACD remains mildly bullish. The Bollinger Bands indicate a bullish stance on the weekly timeframe but are mildly bearish monthly. The KST is bullish weekly but bearish monthly, and the Dow Theory shows a mildly bullish trend on a monthly basis. Overall, the technical stance is bullish, albeit with some mixed signals in the longer timeframes.\n\nIn terms of performance, Biogen has underperformed against the S&P 500 over the year and longer periods, with a 1-year return of -11.34% compared to the S&P 500's 19.89%, and a 3-year return of -45.57% versus 76.66% for the index...."
      },
      {
        "title": "Is Biogen, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biogen-inc-overvalued-or-undervalued-3637553",
        "imagepath": "",
        "date": "2025-10-21 12:04:34",
        "description": "As of 17 October 2025, the valuation grade for Biogen, Inc. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 13, an EV to EBITDA of 9.17, and a PEG ratio of 0.61. In comparison, peers such as the industry average P/E of approximately 13.57 and an EV to EBITDA of 8.89 suggest that Biogen is slightly below the average in terms of valuation ratios.\n\nDespite the attractive valuation, Biogen has underperformed significantly against the S&P 500, with a 1-year return of -24.56% compared to the index's 14.08%. This trend continues over longer periods, with a 5-year return of -48.93% versus the S&P's 91.29%, highlighting the challenges the company faces in the market...."
      },
      {
        "title": "Biogen, Inc. Experiences Valuation Adjustment Amidst Market Performance Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/biogens-valuation-grade-downgraded-from-very-attractive-to-attractive-3640537",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BiogenInc_valuationdot_3640537.png",
        "date": "2025-10-20 15:37:13",
        "description": "Biogen, Inc. has recently adjusted its valuation, with a P/E ratio of 13 and a price-to-book value of 1.34. Despite competitive valuation metrics, the company has struggled in performance, significantly lagging behind the S&P 500 over one, three, and five-year periods, necessitating careful monitoring of its market strategies."
      },
      {
        "title": "Biogen, Inc. Experiences Evaluation Revision Amidst Mixed Market Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/biogen-inc-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-price-increase-3640360",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BiogenInc_technicaldot_3640360.png",
        "date": "2025-10-20 15:13:00",
        "description": "Biogen, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock showing a slight increase. Over the past year, the company has experienced a significant decline compared to the S&P 500. Technical indicators present a mixed performance, reflecting the complexities of its market position."
      },
      {
        "title": "Is Biogen, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biogen-inc-overvalued-or-undervalued-3634421",
        "imagepath": "",
        "date": "2025-10-20 12:22:08",
        "description": "As of 17 October 2025, Biogen, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued, with a P/E ratio of 13, an EV to EBITDA of 9.17, and a PEG ratio of 0.61, indicating a potentially favorable investment opportunity relative to its earnings growth. In comparison, its peer, which has a P/E of approximately 13.57 and an EV to EBITDA of 8.89, suggests that Biogen may be trading at a discount to its competitors.\n\nDespite this attractive valuation, Biogen's stock has significantly underperformed against the S&P 500, with a one-year return of -24.56% compared to the index's 14.08%. This stark contrast in performance may reflect market concerns that could affect future growth prospects...."
      },
      {
        "title": "Is Biogen, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-biogen-inc-overvalued-or-undervalued-3631960",
        "imagepath": "",
        "date": "2025-10-19 11:59:41",
        "description": "As of 17 October 2025, the valuation grade for Biogen, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued at its current price of $143.00, especially when considering its P/E ratio of 13, which is higher than the peer average of approximately 13.57, and an EV to EBITDA ratio of 9.17 compared to the peer average of 8.89. Additionally, the PEG ratio of 0.61 suggests that the stock may not be as undervalued as it seems relative to its growth prospects.\n\nIn terms of peer comparison, Biogen's P/E ratio is slightly below that of its closest competitor, while its EV to EBITDA ratio is higher, indicating a potential premium on valuation. The company's recent performance has been disappointing, with a year-to-date return of -6.49%, significantly lagging behind the S&P 500's 13.30% return, and a staggering -48.93% return over the past five ye..."
      }
    ],
    "total": 22,
    "sid": "1151226",
    "stock_news_url": "https://www.marketsmojo.com/news/biogen-inc-1151226"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Biogen, Inc. technically bullish or bearish?

2025-11-05 11:19:31

As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and Bollinger Bands show a bearish signal on the monthly timeframe. The KST is bullish on the weekly and mildly bullish on the monthly, while Dow Theory indicates a mildly bullish trend on the weekly but no trend on the monthly. Despite the current bullish trend, Biogen's performance has been significantly underwhelming compared to the S&P 500, with a -14.07% return over the past year versus the S&P 500's 19.89%. Overall, the technical stance is bullish but with caution due to mixed signals in longer timeframes....

Is Biogen, Inc. technically bullish or bearish?

2025-11-04 11:30:58

As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by a bullish daily moving average. However, the monthly MACD remains mildly bullish, and the Bollinger Bands indicate a mildly bearish stance for the monthly period. The KST shows a bullish signal weekly but bearish monthly, while the Dow Theory reflects a mildly bullish trend on a monthly basis. The OBV is mildly bullish for both weekly and monthly periods. Despite the bullish indicators, Biogen's performance has lagged significantly behind the S&P 500, with a year-to-date return of -0.97% compared to the S&P 500's 16.30%, and a one-year return of -12.86% versus 19.89% for the index. Overall, the current technical stance is bullish, but the strength is tempered by underperformance relative to the benchmark....

Is Biogen, Inc. technically bullish or bearish?

2025-11-03 11:30:07

As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the monthly KST is bearish, suggesting some mixed signals. The Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, adding to the complexity of the trend. In terms of performance, Biogen has underperformed against the S&P 500 across multiple periods, with a year-to-date return of 0.88% compared to the S&P 500's 16.30%, and a one-year return of -11.34% versus 19.89% for the index. Overall, the current technical stance is bullish, but the strength is tempered by some bearish indicators in the monthly timeframe....

Is Biogen, Inc. technically bullish or bearish?

2025-11-02 11:16:07

As of 31 October 2025, the technical trend for Biogen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by a bullish daily moving average, while the monthly MACD remains mildly bullish. The Bollinger Bands indicate a bullish stance on the weekly timeframe but are mildly bearish monthly. The KST is bullish weekly but bearish monthly, and the Dow Theory shows a mildly bullish trend on a monthly basis. Overall, the technical stance is bullish, albeit with some mixed signals in the longer timeframes. In terms of performance, Biogen has underperformed against the S&P 500 over the year and longer periods, with a 1-year return of -11.34% compared to the S&P 500's 19.89%, and a 3-year return of -45.57% versus 76.66% for the index....

Is Biogen, Inc. overvalued or undervalued?

2025-10-21 12:04:34

As of 17 October 2025, the valuation grade for Biogen, Inc. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 13, an EV to EBITDA of 9.17, and a PEG ratio of 0.61. In comparison, peers such as the industry average P/E of approximately 13.57 and an EV to EBITDA of 8.89 suggest that Biogen is slightly below the average in terms of valuation ratios. Despite the attractive valuation, Biogen has underperformed significantly against the S&P 500, with a 1-year return of -24.56% compared to the index's 14.08%. This trend continues over longer periods, with a 5-year return of -48.93% versus the S&P's 91.29%, highlighting the challenges the company faces in the market....

Biogen, Inc. Experiences Valuation Adjustment Amidst Market Performance Challenges

2025-10-20 15:37:13

Biogen, Inc. has recently adjusted its valuation, with a P/E ratio of 13 and a price-to-book value of 1.34. Despite competitive valuation metrics, the company has struggled in performance, significantly lagging behind the S&P 500 over one, three, and five-year periods, necessitating careful monitoring of its market strategies.

Biogen, Inc. Experiences Evaluation Revision Amidst Mixed Market Performance Indicators

2025-10-20 15:13:00

Biogen, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock showing a slight increase. Over the past year, the company has experienced a significant decline compared to the S&P 500. Technical indicators present a mixed performance, reflecting the complexities of its market position.

Is Biogen, Inc. overvalued or undervalued?

2025-10-20 12:22:08

As of 17 October 2025, Biogen, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued, with a P/E ratio of 13, an EV to EBITDA of 9.17, and a PEG ratio of 0.61, indicating a potentially favorable investment opportunity relative to its earnings growth. In comparison, its peer, which has a P/E of approximately 13.57 and an EV to EBITDA of 8.89, suggests that Biogen may be trading at a discount to its competitors. Despite this attractive valuation, Biogen's stock has significantly underperformed against the S&P 500, with a one-year return of -24.56% compared to the index's 14.08%. This stark contrast in performance may reflect market concerns that could affect future growth prospects....

Is Biogen, Inc. overvalued or undervalued?

2025-10-19 11:59:41

As of 17 October 2025, the valuation grade for Biogen, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued at its current price of $143.00, especially when considering its P/E ratio of 13, which is higher than the peer average of approximately 13.57, and an EV to EBITDA ratio of 9.17 compared to the peer average of 8.89. Additionally, the PEG ratio of 0.61 suggests that the stock may not be as undervalued as it seems relative to its growth prospects. In terms of peer comparison, Biogen's P/E ratio is slightly below that of its closest competitor, while its EV to EBITDA ratio is higher, indicating a potential premium on valuation. The company's recent performance has been disappointing, with a year-to-date return of -6.49%, significantly lagging behind the S&P 500's 13.30% return, and a staggering -48.93% return over the past five ye...

View All News